The real-world safety profile of tisagenlecleucel appears to be more favourable than that reported in the JULIET study, which led to its FDA approval.

Taking a patient's immune cells and targeting their cancer with them, which is called CAR T cell therapy, is showing promise ...

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...